Department of Pathology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.
Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.
J Neurosci. 2018 May 2;38(18):4288-4300. doi: 10.1523/JNEUROSCI.1280-17.2018. Epub 2018 Apr 9.
HIV-associated neurocognitive disorders (HANDs) share common symptoms with Alzheimer's disease (AD), which is characterized by amyloid-β (Aβ) plaques. Plaques are formed by aggregation of Aβ oligomers, which may be the toxic species in AD pathogenesis, and oligomers are generated by cleavage of amyloid precursor protein (APP) by β-site amyloid precursor protein cleaving enzyme 1 (BACE1). BACE1 inhibitors reverse neuronal loss and cognitive decline in animal models of AD. Although studies have also found evidence of altered APP processing in HIV patients, it is unknown whether increased BACE1 expression or Aβ oligomer production is a common neuropathological feature of HAND. Moreover, it is unknown whether BACE1 or APP is involved in the excitotoxic, NMDAR-dependent component of HIV-associated neurotoxicity Herein, we hypothesize that HIV-associated neurotoxicity is mediated by NMDAR-dependent elevation of BACE1 and subsequent altered processing of APP. Supporting this, we observed elevated levels of BACE1 and Aβ oligomers in CNS of male and female HIV patients. In a model of HIV-associated neurotoxicity in which rat neurons are treated with supernatants from HIV-infected human monocyte-derived macrophages, we observed NMDAR-dependent elevation of BACE1 protein. NMDA treatment also increased BACE1 and both pharmacological BACE1 inhibition and genetic loss of APP were partially neuroprotective. Moreover, in APP knock-out (APP) mouse neurons, NMDA-induced toxicity was BACE1 independent, indicating that cytotoxicity of BACE1 is dependent upon APP cleavage. Our findings suggest that increased BACE1 and the resultant Aβ oligomer production may contribute to HIV-associated neuropathogenesis and inhibition of BACE1 could have therapeutic potential in HANDs. HIV-associated neurocognitive disorders (HANDs) represent a range of cognitive impairments affecting ∼50% of HIV individuals. The specific causes of HAND are unknown, but evidence suggests that HIV-infected macrophage infiltration into the brain may cause neuronal damage. Herein, we show that neurons treated with conditioned media from HIV-infected macrophages have increased expression of β-site amyloid precursor protein cleaving enzyme 1 (BACE1), a protein implicated in Alzheimer's disease pathogenesis. Moreover, inhibition of BACE1 prevented neuronal loss after conditioned media exposure, but had no effect on HIV-associated neurotoxicity in neurons lacking its cleavage target amyloid precursor protein. We also observed increased BACE1 expression in HIV patient brain tissue, confirming the potential relevance of BACE1 as a therapeutic target in HANDs.
HIV 相关神经认知障碍 (HANDs) 与阿尔茨海默病 (AD) 具有共同的症状,AD 的特征是淀粉样β (Aβ) 斑块。斑块是由 Aβ 寡聚体的聚集形成的,Aβ 寡聚体可能是 AD 发病机制中的毒性物质,而寡聚体是由淀粉样前体蛋白 (APP) 被β-位点淀粉样前体蛋白裂解酶 1 (BACE1) 裂解产生的。BACE1 抑制剂可逆转 AD 动物模型中的神经元丢失和认知衰退。尽管研究还发现了 HIV 患者 APP 加工改变的证据,但尚不清楚 BACE1 表达增加或 Aβ 寡聚体产生是否是 HAND 的共同神经病理学特征。此外,尚不清楚 BACE1 或 APP 是否参与 HIV 相关性神经毒性的兴奋性 NMDAR 依赖性成分。在此,我们假设 HIV 相关性神经毒性是由 NMDAR 依赖性 BACE1 升高和随后 APP 加工改变介导的。支持这一观点的是,我们观察到男性和女性 HIV 患者中枢神经系统中 BACE1 和 Aβ 寡聚体水平升高。在 HIV 感染的人单核细胞衍生巨噬细胞上清液处理的 HIV 相关性神经毒性模型中,我们观察到 NMDAR 依赖性 BACE1 蛋白升高。NMDA 处理也增加了 BACE1,而药理学 BACE1 抑制和 APP 基因缺失均具有部分神经保护作用。此外,在 APP 敲除 (APP) 小鼠神经元中,NMDA 诱导的毒性与 BACE1 无关,表明 BACE1 的细胞毒性依赖于 APP 的裂解。我们的研究结果表明,BACE1 的增加和由此产生的 Aβ 寡聚体产生可能导致 HIV 相关性神经发病机制,并抑制 BACE1 可能具有 HAND 的治疗潜力。HIV 相关神经认知障碍 (HANDs) 代表影响约 50% HIV 个体的一系列认知障碍。HAND 的具体原因尚不清楚,但有证据表明,HIV 感染的巨噬细胞浸润大脑可能导致神经元损伤。在此,我们表明,用 HIV 感染的巨噬细胞条件培养基处理的神经元表达增加β-位点淀粉样前体蛋白裂解酶 1 (BACE1),该蛋白与阿尔茨海默病发病机制有关。此外,抑制 BACE1 可防止条件培养基暴露后的神经元丢失,但对缺乏其裂解靶标淀粉样前体蛋白的神经元中的 HIV 相关性神经毒性没有影响。我们还观察到 HIV 患者脑组织中 BACE1 表达增加,证实了 BACE1 作为 HAND 治疗靶点的潜在相关性。